Monthly Subscription
Unlimited document downloads
$99


Custom Document Search
Locate hard-to-find documents, quickly and inexpensively
$59

See also:

company_intel Gilead Sciences, Inc.


The Consus Group provides critical intelligence for the
business, investor, and legal communities.

Documents can be downloaded immediately after purchase. Complete your order by clicking the Add-to-Cart button.

$88
 Subscribers Subscribers
Preview 		2003
 ContractIntelligence Annual Report to Shareholders AMD;
Aeropostale;
AFLAC 		Agrium
Entity 2 3 4 5 6
Bank 2 3 4 5 6
$99
 Subscribers Subscribers
Preview 		2003
 ContractIntelligence Annual Report to Shareholders AMD;
Aeropostale;
AFLAC 		Agrium
Entity 2 3 4 5 6
Bank 2 3 4 5 6
$48
 Subscribers Subscribers
Preview 		2007
 ContractIntelligence Certificate of Secretary Gilead Sciences, Inc.
$39
 Subscribers Subscribers
2004
 ContractIntelligence Certifications Gilead Sciences, Inc.
$39
 Subscribers Subscribers
2004
 ContractIntelligence Certifications Gilead Sciences, Inc.
$36
 Subscribers Subscribers
2002
 ContractIntelligence Conference Call Cubist Pharma;
Gilead Sciences 		Novartis
$36
 Subscribers Subscribers
2002
 ContractIntelligence Cubist and Gilead End European Commercialization Agreement for Investigational Antibiotic Cidecin(R) Cubist Pharma;
Gilead Sciences 		Novartis Pharma
$35
 Subscribers Subscribers
2001
 Cubist Pharmaceuticals and DSM Fine Chemicals Announce Opening of Daptomycin Manufacturing Facility Cubist Pharma;
Gilead Sciences 		Merck;
Novartis Pharma
$39
 Subscribers Subscribers
2001
 ContractIntelligence Cubist Pharmaceuticals and Gilead Sciences Announce European Commercialization Agreement for Investigational Antibacterial Agent Cidecin(TM) Cubist Pharma;
Gilead Sciences;
Merck 		Novartis Pharma;
Schering-Plough
$35
 Subscribers Subscribers
Preview 		2001
 ContractIntelligence Cubist Pharmaceuticals Announces Issuance of Patent Covering Oral Formulations of Ceftriaxone International Health Management Associates, Inc.;
Cubist Pharma;
Gilead Sciences 		Merck;
Novartis Pharma
$34
 Subscribers Subscribers
Preview 		2002
 ContractIntelligence Cubist Pharmaceuticals Announces Results from First Phase III Cidecin(R) Community-Acquired Pneumonia Trial Cubist Pharma;
Gilead Sciences 		Merck;
Novartis Pharma
$35
 Subscribers Subscribers
2001
 Cubist Pharmaceuticals Appoints Dinu Sen President and Chief Operating Officer Amgen;
Cubist Pharma;
Gilead Sciences 		Merck
Entity 2 3
$31
 Subscribers Subscribers
2003
 ContractIntelligence Cubist Pharmaceuticals Reports First-Quarter 2003 Results Cubist Pharma;
Gilead Sciences 		Novartis
$35
 Subscribers Subscribers
2001
 ContractIntelligence Cubist Pharmaceuticals Reports First-Quarter Results Cubist Pharma;
Gilead Sciences 		Merck;
Novartis Pharma
$38
 Subscribers Subscribers
2003
 ContractIntelligence Cubist Pharmaceuticals Reports Third-Quarter 2003 Results Cubist Pharmaceuticals Inc. Gilead Sciences, Inc.
$37
 Subscribers Subscribers
Preview 		2004
 For Immediate Release Eyetech Pharma;
Forest Labs;
Gilead Sciences 		ISIS Pharma;
Nektar;
Pfizer
$33
 Subscribers Subscribers
Preview 		2004
 For Immediate Release Gilead Sciences, Inc.
$42
 Subscribers Subscribers
Preview 		2004
 For Immediate Release Eyetech Pharmaceuticals, Inc. Gilead Sciences, Inc.
$37
 Subscribers Subscribers
Preview 		2004
 For Immediate Release Gilead Sciences, Inc.
$38
 Subscribers Subscribers
Preview 		2004
 For Immediate Release Eyetech Pharmaceuticals, Inc. Gilead Sciences, Inc.